Hypertension
Effects of antihypertensive AT(1)R antisense gene therapy are independent of endothelial function
Published in Gene Therapy Weekly, September 11th, 2003
"It has previously been established that a single systemic administration of retroviral vector containing angiotensin 11 type I receptor antisense (AT(1)R-AS) in the neonatal spontaneously hypertensive rat (SHR) prevents development of hypertension, and in addition cardiac hypertrophy and endothelial dysfunction," researchers in the United States explained. "However, these studies could not determine whether the effects of AT(1)R-AS on high blood pressure (BP) and endothelial function were independent."
"Angiotensin receptor blockers have...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-09-11)
More Articles from Gene Therapy Weekly
- Cancer Therapy
Stat5 inhibition produces death in human prostate cancer cells - Brain Cancer
Histone H2AX sensitizes glioma cells to genotoxic stimuli - Cardiology
Angiogenic gene therapy has shown potential benefits in human clinical trials - Chemotherapy
Gene and prodrug therapy won't override ABCG2-mediated drug resistance - Virology
The marmoset can be incorporated into preclinical gene therapy trials - Bacteriology
Cyclic mechanisms characterize the nature of biofilms and gene transfer - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
